Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.87 USD | +13.43% | +23.88% | -21.16% |
05-09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.16% | 629M | C | ||
+7.52% | 113B | B+ | ||
+11.38% | 106B | B+ | ||
-12.64% | 22.22B | B+ | ||
+0.44% | 22.27B | B | ||
-4.18% | 19.43B | A- | ||
-37.85% | 17.87B | A- | ||
-8.58% | 17.24B | B | ||
+37.41% | 12.52B | C+ | ||
-23.95% | 8.34B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALT Stock
- Ratings Altimmune, Inc.